Skip to main content
ZYME logo

ZYME · Zymeworks Inc. · Webcasts, Transcripts & Audio

Track ZYME — free
$26.00 -0.04 (-0.15%) Play latest call Q1 2026 earnings call transcript
Market Cap
$1.80B
Shares
69.03M
Volume · Nov 18 1.09M Avg daily vol (3M) 1.08M

Zymeworks Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Zymeworks Inc. (ZYME), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Conference
Investor event
2026-11-17
Zymeworks Inc. (ZYME) November 17, 2026 Conference
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-11-12
Zymeworks Inc. (ZYME) November 12, 2026 Conference
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-11-11
Zymeworks Inc. (ZYME) November 11, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-11-10
Zymeworks Inc. (ZYME) November 10, 2026 Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q3
2026-11-09
Zymeworks Inc. (ZYME) Q3 2026 Earnings Call
Revenue
$256.46M
▲ 828.7% YoY
Diluted EPS
$2.28
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-09-28
Zymeworks Inc. (ZYME) September 28, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-09-28
Zymeworks Inc. (ZYME) Q2 2026 Earnings Call
Revenue
$4.59M
▼ 90.6% YoY
Diluted EPS
$-0.62
▼ 2166.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-09-14
Zymeworks Inc. (ZYME) September 14, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-09-08
Zymeworks Inc. (ZYME) September 8, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-06-03
Zymeworks Inc. (ZYME) June 3, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-07
Zymeworks Inc. (ZYME) Q1 2026 Earnings Call Transcript
Confident tone ADC pipeline and AACR data Zanidatamab regulatory milestones Royalty aggregation business model
Revenue
$2.41M
▼ 91.1% YoY
Diluted EPS
$-0.59
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-04-21
Zymeworks Inc. (ZYME) April 21, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q4
2026-03-02
Zymeworks Inc. (ZYME) Q4 2025 Earnings Call Transcript
Confident tone Royalty Pharma royalty-backed note financing Royalty and milestone economics from collaborations Zanidatumab GEA regulatory and commercial progress
Revenue
$2.52M*
▼ 91.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Zymeworks Inc. (ZYME) Q3 2025 Earnings Call Transcript
Confident tone ZW191 Phase I ADC (folate receptor alpha) ZW251 Phase I ADC (GPC3, hepatocellular carcinoma) DLL3 T-cell engager (preclinical/ZW171)
Revenue
$27.61M
▲ 72.6% YoY
Diluted EPS
$-0.26
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Zymeworks Inc. (ZYME) Q2 2025 Earnings Call Transcript
Confident tone Wholly-owned ADC pipeline (ZW171, ZW191, ZW251, ZW220) Preclinical IL-4/IL-33 bispecific (ZW1528) for COPD Timing and disclosure of ZW191 data
Revenue
$48.73M
▲ 153.2% YoY
Diluted EPS
$0.03
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Zymeworks Inc. (ZYME) Q1 2025 Earnings Call Transcript
Positive tone Bispecific T-cell engager vs ADC strategy Pipeline and preclinical data Partnerships and milestones
Revenue
$27.11M
▲ 170.3% YoY
Diluted EPS
$-0.30
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-01-08
Zymeworks Inc. (ZYME) Q4 2024 Earnings Call Transcript
Positive tone Partnership milestones and revenue ADC programs (ZW251, ZW220, ZW191) Financial performance and operating expenses
Revenue
$31.03M*
▲ 83.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-10-31
Zymeworks Inc. (ZYME) Q3 2024 Earnings Call Transcript
Positive tone Partner programs and licensing revenue Wholly owned pipeline progress (ZW171, ZW191, ZW220, ZW251) Zanidatamab (Zani) updates with Jazz Pharmaceuticals
Revenue
$16.00M
▼ 3.1% YoY
Diluted EPS
$-0.39
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-01
Zymeworks Inc. (ZYME) Q2 2024 Earnings Call Transcript
Positive tone Wholly-owned pipeline advancement Zanidatamab regulatory progress Mesothelin T-cell engager safety and design (ZW171)
Revenue
$19.24M
▲ 174.8% YoY
Diluted EPS
$-0.49
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-02
Zymeworks Inc. (ZYME) Q1 2024 Earnings Call Transcript
Confident tone Zanidatamab Partnership Progress TriTCE Trispecific Platform Preclinical Pipeline / ADC and Multispecifics
Revenue
$10.03M
▼ 71.8% YoY
Diluted EPS
$-0.42
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-06
Zymeworks Inc. (ZYME) Q4 2023 Earnings Call Transcript
Confident tone Zanidatamab commercial outlook Partner execution (Jazz/BeiGene) 5x5 early-stage pipeline
Revenue
$16.93M*
▼ 95.8% YoY
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Zymeworks Inc. (ZYME) Q3 2023 Earnings Call Transcript
Revenue
$16.51M
▲ 527.4% YoY
Diluted EPS
$-0.41
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-10
Zymeworks Inc. (ZYME) Q2 2023 Earnings Call Transcript
Revenue
$7.00M
▲ 28.7% YoY
Diluted EPS
$-0.76
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-08
Zymeworks Inc. (ZYME) Q1 2023 Earnings Call Transcript
Revenue
$35.58M
▲ 1756.9% YoY
Diluted EPS
$-0.37
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-07
Zymeworks Inc. (ZYME) Q4 2022 Earnings Call Transcript
Revenue
$402.49M*
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-08
Zymeworks Inc. (ZYME) Q3 2022 Earnings Call Transcript
Revenue
$2.63M
▼ 40.1% YoY
Diluted EPS
$-0.72
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-06-30
Date not confirmed
Zymeworks Inc. (ZYME) Q2 2022 Earnings Call Transcript
Revenue
$5.44M
Diluted EPS
$-0.97
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-03-31
Date not confirmed
Zymeworks Inc. (ZYME) Q1 2022 Earnings Call Transcript
Revenue
$1.92M
Diluted EPS
$-1.19
Rev · 2q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2021-12-31
Date not confirmed
Zymeworks Inc. (ZYME) Q4 2021 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Showing 1–29 of 29 webcasts
Key facts CIK 1937653 CUSIP 98985Y108 13F (30d) 206 filings 192 filers Visit website Investor relations